Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Hydrogen isotope fractionation in methane plasma.

Robert F, Derenne S, Lombardi G, Hassouni K, Michau A, Reinhardt P, Duhamel R, Gonzalez A, Biron K.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):870-874. doi: 10.1073/pnas.1615767114. Epub 2017 Jan 17.

2.

Major Histocompatibility Complex class I proteins are critical for maintaining neuronal structural complexity in the aging brain.

Lazarczyk MJ, Kemmler JE, Eyford BA, Short JA, Varghese M, Sowa A, Dickstein DR, Yuk FJ, Puri R, Biron KE, Leist M, Jefferies WA, Dickstein DL.

Sci Rep. 2016 May 27;6:26199. doi: 10.1038/srep26199.

3.

Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's disease.

Jefferies WA, Price KA, Biron KE, Fenninger F, Pfeifer CG, Dickstein DL.

Alzheimers Res Ther. 2013 Dec 19;5(6):64. doi: 10.1186/alzrt230. eCollection 2013. Review.

4.

Cessation of neoangiogenesis in Alzheimer's disease follows amyloid-beta immunization.

Biron KE, Dickstein DL, Gopaul R, Fenninger F, Jefferies WA.

Sci Rep. 2013;3:1354. doi: 10.1038/srep01354.

5.

Improving myoelectric pattern recognition positional robustness using advanced training protocols.

Scheme E, Biron K, Englehart K.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:4828-31. doi: 10.1109/IEMBS.2011.6091196.

PMID:
22255419
6.

Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease.

Biron KE, Dickstein DL, Gopaul R, Jefferies WA.

PLoS One. 2011;6(8):e23789. doi: 10.1371/journal.pone.0023789. Epub 2011 Aug 31.

7.

Candidate anti-herpesviral drugs; mechanisms of action and resistance.

Biron KK.

In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. Chapter 68.

8.

Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE.

Bennett J, Basivireddy J, Kollar A, Biron KE, Reickmann P, Jefferies WA, McQuaid S.

J Neuroimmunol. 2010 Dec 15;229(1-2):180-91. doi: 10.1016/j.jneuroim.2010.08.011. Epub 2010 Sep 15.

PMID:
20832870
9.

GSK983: a novel compound with broad-spectrum antiviral activity.

Harvey R, Brown K, Zhang Q, Gartland M, Walton L, Talarico C, Lawrence W, Selleseth D, Coffield N, Leary J, Moniri K, Singer S, Strum J, Gudmundsson K, Biron K, Romines KR, Sethna P.

Antiviral Res. 2009 Apr;82(1):1-11. doi: 10.1016/j.antiviral.2008.12.015. Epub 2009 Jan 31.

PMID:
19187793
10.

Antiviral drugs for cytomegalovirus diseases.

Biron KK.

Antiviral Res. 2006 Sep;71(2-3):154-63. Epub 2006 May 23. Review.

PMID:
16765457
11.

Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease.

Dickstein DL, Biron KE, Ujiie M, Pfeifer CG, Jeffries AR, Jefferies WA.

FASEB J. 2006 Mar;20(3):426-33. Erratum in: FASEB J. 2006 Jul;20(9):1573.

PMID:
16507760
12.

Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.

Chou S, Marousek GI, Senters AE, Davis MG, Biron KK.

J Virol. 2004 Jul;78(13):7124-30.

13.

Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections.

Kern ER, Hartline CB, Rybak RJ, Drach JC, Townsend LB, Biron KK, Bidanset DJ.

Antimicrob Agents Chemother. 2004 May;48(5):1749-55.

14.

Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus.

Underwood MR, Ferris RG, Selleseth DW, Davis MG, Drach JC, Townsend LB, Biron KK, Boyd FL.

Antimicrob Agents Chemother. 2004 May;48(5):1647-51.

15.

Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain.

Lizée G, Basha G, Tiong J, Julien JP, Tian M, Biron KE, Jefferies WA.

Nat Immunol. 2003 Nov;4(11):1065-73. Epub 2003 Oct 19.

PMID:
14566337
16.

The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase.

Krosky PM, Baek MC, Jahng WJ, Barrera I, Harvey RJ, Biron KK, Coen DM, Sethna PB.

J Virol. 2003 Jul;77(14):7720-7.

17.

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, Drach JC, Townsend LB, Underwood MR, Biron KK, Kern ER.

Antimicrob Agents Chemother. 2003 Jul;47(7):2186-92.

18.

Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.

Selleseth DW, Talarico CL, Miller T, Lutz MW, Biron KK, Harvey RJ.

Antimicrob Agents Chemother. 2003 Apr;47(4):1468-71.

19.

Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication.

Koszalka GW, Johnson NW, Good SS, Boyd L, Chamberlain SC, Townsend LB, Drach JC, Biron KK.

Antimicrob Agents Chemother. 2002 Aug;46(8):2373-80.

20.

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA 3rd, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, Stanat SC, Drach JC, Townsend LB, Koszalka GW.

Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72.

21.

Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus.

Krosky PM, Borysko KZ, Nassiri MR, Devivar RV, Ptak RG, Davis MG, Biron KK, Townsend LB, Drach JC.

Antimicrob Agents Chemother. 2002 Feb;46(2):478-86.

22.

Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8.

Jabs DA, Martin BK, Forman MS, Dunn JP, Davis JL, Weinberg DV, Biron KK, Baldanti F, Hu H; Cytomegalovirus Retinitis and Viral Resistance Study Group.

Am J Ophthalmol. 2001 Nov;132(5):700-10.

PMID:
11704031
23.

Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94.

McSharry JJ, McDonough A, Olson B, Talarico C, Davis M, Biron KK.

Clin Diagn Lab Immunol. 2001 Nov;8(6):1279-81.

24.

Differences in DNA packaging genes and sensitivity to benzimidazole ribonucleosides between human cytomegalovirus strains AD169 and Towne.

Krosky PM, Ptak RG, Underwood MR, Biron KK, Townsend LB, Drach JC.

Antivir Chem Chemother. 2000 Sep;11(5):349-52.

PMID:
11142634
25.

Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.

Jabs DA, Martin BK, Forman MS, Dunn JP, Davis JL, Weinberg DV, Biron KK, Baldanti F; Cytomegalovirus Retinitis and Viral Resistance Study Group.

J Infect Dis. 2001 Jan 15;183(2):333-337. Epub 2000 Dec 15.

PMID:
11120934
26.

Phosphorylation of ganciclovir phosphonate by cellular GMP kinase determines the stereoselectivity of anti-human cytomegalovirus activity.

Miller WH, Beauchamp LM, Meade E, Reardon JE, Biron KK, Smith AA, Goss CA, Miller RL.

Nucleosides Nucleotides Nucleic Acids. 2000 Jan-Feb;19(1-2):341-56.

PMID:
10772719
27.

Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94).

Chan JH, Chamberlain SD, Biron KK, Davis MG, Harvey RJ, Selleseth DW, Dornsife RE, Dark EH, Frick LW, Townsend LB, Drach JC, Koszalka GW.

Nucleosides Nucleotides Nucleic Acids. 2000 Jan-Feb;19(1-2):101-23. Erratum in: Nucleosides Nucleotides Nucleic Acids. 2002;21(1):109.

PMID:
10772705
28.

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.

Landry ML, Stanat S, Biron K, Brambilla D, Britt W, Jokela J, Chou S, Drew WL, Erice A, Gilliam B, Lurain N, Manischewitz J, Miner R, Nokta M, Reichelderfer P, Spector S, Weinberg A, Yen-Lieberman B, Crumpacker C.

Antimicrob Agents Chemother. 2000 Mar;44(3):688-92.

29.

Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease.

Chulay J, Biron K, Wang L, Underwood M, Chamberlain S, Frick L, Good S, Davis M, Harvey R, Townsend L, Drach J, Koszalka G.

Adv Exp Med Biol. 1999;458:129-34. Review.

PMID:
10549385
31.

Studies designed to increase the stability and antiviral activity (HCMV) of the active benzimidazole nucleoside, TCRB.

Townsend LB, Gudmundsson KS, Daluge SM, Chen JJ, Zhu Z, Koszalka GW, Boyd L, Chamberlain SD, Freeman GA, Biron KK, Drach JC.

Nucleosides Nucleotides. 1999 Apr-May;18(4-5):509-19.

PMID:
10432642
32.

Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.

Talarico CL, Burnette TC, Miller WH, Smith SL, Davis MG, Stanat SC, Ng TI, He Z, Coen DM, Roizman B, Biron KK.

Antimicrob Agents Chemother. 1999 Aug;43(8):1941-6.

33.

Emergence of a ganciclovir-resistant human cytomegalovirus strain with a new UL97 mutation in an AIDS patient.

Baldanti F, Simoncini L, Talarico CL, Sarasini A, Biron KK, Gerna G.

AIDS. 1998 May 7;12(7):816-8. No abstract available.

PMID:
9619816
34.

Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56.

Krosky PM, Underwood MR, Turk SR, Feng KW, Jain RK, Ptak RG, Westerman AC, Biron KK, Townsend LB, Drach JC.

J Virol. 1998 Jun;72(6):4721-8.

35.

The Cys607-->Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients.

Baldanti F, Underwood MR, Talarico CL, Simoncini L, Sarasini A, Biron KK, Gerna G.

Antimicrob Agents Chemother. 1998 Feb;42(2):444-6.

36.

Interpreting human cytomegalovirus antiviral drug susceptibility testing: the role of mixed virus populations.

Baldanti F, Biron KK, Gerna G.

J Infect Dis. 1998 Mar;177(3):823-4. No abstract available.

PMID:
9498475
37.

Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product.

Underwood MR, Harvey RJ, Stanat SC, Hemphill ML, Miller T, Drach JC, Townsend LB, Biron KK.

J Virol. 1998 Jan;72(1):717-25.

38.

In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.

Cullen JM, Smith SL, Davis MG, Dunn SE, Botteron C, Cecchi A, Linsey D, Linzey D, Frick L, Paff MT, Goulding A, Biron K.

Antimicrob Agents Chemother. 1997 Oct;41(10):2076-82.

39.

The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines.

He Z, He YS, Kim Y, Chu L, Ohmstede C, Biron KK, Coen DM.

J Virol. 1997 Jan;71(1):405-11.

40.

Partial substitution of the functions of the herpes simplex virus 1 U(L)13 gene by the human cytomegalovirus U(L)97 gene.

Ng TI, Talarico C, Burnette TC, Biron K, Roizman B.

Virology. 1996 Nov 15;225(2):347-58.

42.

Cytomegalovirus: genetics of drug resistance.

Biron KK.

Adv Exp Med Biol. 1996;394:135-43. Review. No abstract available.

PMID:
8815680
43.

Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir.

Hanson MN, Preheim LC, Chou S, Talarico CL, Biron KK, Erice A.

Antimicrob Agents Chemother. 1995 May;39(5):1204-5.

44.

Antiviral resistance in clinical practice.

Kimberlin DW, Crumpacker CS, Straus SE, Biron KK, Drew WL, Hayden FG, McKinlay M, Richman DD, Whitley RJ.

Antiviral Res. 1995 Apr;26(4):423-38. Review. No abstract available.

PMID:
7574544
45.

Assays for antiviral drug resistance.

Kimberlin DW, Spector SA, Hill EL, Biron KK, Hay AJ, Mayers DL, Whitley RJ.

Antiviral Res. 1995 Apr;26(4):403-13. Review. No abstract available.

PMID:
7574542
46.

Molecular mechanisms of antiviral resistance.

Kimberlin DW, Coen DM, Biron KK, Cohen JI, Lamb RA, McKinlay M, Emini EA, Whitley RJ.

Antiviral Res. 1995 Apr;26(4):369-401. Review. No abstract available.

PMID:
7574541
47.

Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.

Chou S, Erice A, Jordan MC, Vercellotti GM, Michels KR, Talarico CL, Stanat SC, Biron KK.

J Infect Dis. 1995 Mar;171(3):576-83.

PMID:
7876604
48.

A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate.

Baldanti F, Silini E, Sarasini A, Talarico CL, Stanat SC, Biron KK, Furione M, Bono F, Palù G, Gerna G.

J Virol. 1995 Feb;69(2):796-800.

49.
50.

Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS.

Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH Jr.

J Infect Dis. 1994 Jul;170(1):68-75.

PMID:
8014522

Supplemental Content

Support Center